SAN ANTONIO, Texas--(BUSINESS WIRE)--Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite ...
Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response The ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
• MOA: airway muscarinic acetylcholine receptor antagonist • Superior to doubling dose of ICS; non-inferior to ICS+ LABA therapy in African American patients with uncontrolled asthma • Increases time ...
Roshni Naik, MD, allergist at Mount Sinai Health System, discusses the history of present illness for a case of severe asthma with nasal polyps: "Patient is a 45 year-old male with a past medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results